Intracavernous medication for treatment of premature ejaculation.
Sixteen men complained of premature ejaculation during a five-month period between May, 1987, and October, 1987. Eight patients entered this study using intracavernous vasoactive drugs as treatment for their problem. The patients, ages twenty-four through fifty-eight (average 42 years), were all physically healthy and taking no medications. Five patients had normal findings on nocturnal tumescence monitor, while 3 patients did not use the monitor. A mixture of phentolamine mesylate, 1.0 mg/mL, and papaverine hydrochloride, 30 mg/mL, was used. The dosage required was from 0.10 mL to 0.40 mL. All 8 patients responded successfully to this treatment. Three patients stated they were cured and stopped the treatment. The other 5 patients continued using the medication after fourteen months. The drug-induced erection lasted between two and four hours despite ejaculation. There have been no side effects through April, 1988. All patients report satisfaction with the results of this treatment. The study showed that intracavernous medication therapy can be successful in the treatment of premature ejaculation.
Fein
R L
RL
Division of Urology, North Miami Medical Center, Florida.
D000328:Adult; D004338:Drug Combinations; D004542:Ejaculation / Q000187:drug effects*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010208:Papaverine / Q000008:administration & dosage*; D010413:Penis; D010646:Phentolamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012646:Self Administration; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*
D004338:Drug Combinations; D010208:Papaverine; D010646:Phentolamine